The key catalyst is the ASCENTRA-UC topline readout in Q4 2027, with ASCENTRA-CD enrollment initiation in Q1 2027 as a near-term milestone. Cash runway through both readouts reduces near-term financing risk, but the widening net loss and cash burn rate warrant monitoring of the burn trajectory.
Drug in focus
PALI drug pipeline →PALI-2108
● Neutral Named in this 8-K- Impact
- Phase
- Phase 2b
- Time to market
- If Phase 2b succeeds, PALI-2108 would need to advance to Phase 3 trials and then file for FDA approval, a process that typically takes several more years. The earliest potential approval would likely be 2029-2030 at the earliest, assuming successful trials.
- Next catalyst
- None dated
What to watchThe next major catalyst is the Phase 2b ASCENTRA-UC topline data expected in Q4 2027, roughly 12 months away. Positive data would validate PALI-2108's differentiated gut-targeted PDE4 approach in a large, well-controlled study; negative or mixed results would severely impact the stock since PALI-2108 is the company's only clinical-stage asset. Interim milestones to watch include ASCENTRA-CD (Crohn's) first patient dosing targeted for Q1 2027 and any early data presentations at medical conferences.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $1.17entry
- T+1 · 5d ago −2.56%α −2.21% · $1.14
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Palisade Bio reported Q3 2026 net loss of $14.6M ($0.07 per share), wider than the $2.9M loss a year ago, as R&D spending surged to $10.6M to support Phase 2 trials. The key operational milestone was dosing the first patient in the Phase 2b ASCENTRA-UC trial on October 27, 2026, with topline results expected in Q4 2027. Cash of $113.6M is expected to fund operations through both ASCENTRA-UC and ASCENTRA-CD readouts.
Key Financial Metrics
Key Facts
- First patient dosed in Phase 2b ASCENTRA-UC trial on October 27, 2026; topline results expected Q4 2027
- FDA cleared IND for Phase 2a ASCENTRA-CD trial on September 22, 2026; enrollment targeted for Q1 2027
- Net loss of $14.6M for Q3 2026 vs $2.9M in Q3 2025; net loss per share $0.07 vs $0.38
- R&D expenses $10.6M in Q3 2026 vs $1.4M in Q3 2025, driven by Phase 2 start-up costs
- Cash and cash equivalents $113.6M as of September 30, 2026, down from $125.2M at June 30, 2026
- Cash runway expected to fund operations through primary efficacy readouts from both Phase 2 trials
Financial Impact
Q3 2026 net loss $14.6M, cash burn $19.8M year-to-date; cash position $113.6M
Risk Factors
- Clinical trial enrollment delays or failure to meet endpoints in Phase 2 studies
- Cash burn rate of ~$20M per nine months may require additional financing before readouts
- No approved products or revenue; pre-revenue clinical-stage company
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001357459-26-000025 |
| Document: pali-20261110.htm | 0001357459-26-000025 |
| Document: 0001357459-26-000025-index-headers.html | 0001357459-26-000025 |
| Document: 0001357459-26-000025-index.html | 0001357459-26-000025 |
| Document: 0001357459-26-000025.txt | 0001357459-26-000025 |
| 8-K Data (Synthetic) | 0001357459-26-000025 |
Track record
14 reports on PALI
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.08 Now $1.03 −4.19% settles Dec 15
- Nov 10, 20266d ago 8-K Neutral 5/10 Viewing Entry $1.17 Now $1.03 −11.97% settles Dec 10
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $1.13 Now $1.03 −8.85% settles Dec 9
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $1.16 Now $1.03 −11.21% settles Nov 30
- Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
- Sep 22, 20267w ago Press Release Bullish 6/10 Entry $1.69 to $1.43 Now $1.03 −39.05% ▼ −15.38% −14.82% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 Entry $2.14 to $2.05 Now $1.03 −51.87% ▼ −4.21% −3.15% vs SPY
- Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $1.89 to $2.10 Now $1.03 −45.50% ▲ +11.11% +7.93% vs SPY
- Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $1.97 to $2.09 Now $1.03 −47.72% ▲ +6.09% +3.85% vs SPY
- Jun 11, 202622w ago 8-K Neutral 4/10 Entry $1.71 to $1.96 Now $1.03 −39.77% ▲ +14.62% +12.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers